Spero Therapeutics
148 articles with Spero Therapeutics
-
Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update
5/16/2022
Spero Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2022 and provided a business update.
-
Spero Therapeutics to Present at Upcoming Investor Conferences - May 11, 2022
5/11/2022
Spero Therapeutics, Inc. announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 2022 RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, which are taking place May 17-18 and May 23-25, respectively.
-
Spero Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results on Monday, May 16, 2022
5/9/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, May 16, 2022, at 4:30 p.m. ET to report its first quarter 2022 financial results and provide an update on its business and pipeline.
-
ImmunoGen, which is developing Antibody-drug conjugates (ADCs) for the treatment of cancer, is on a hiring spree. The company is looking to hire for more than 200 positions by the end of 2022.
-
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
5/3/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will immediately defer current commercialization activities for tebipenem HBr based on feedback from a recent Late Cycle Meeting (LCM) with the U.S. Food and Drug Administration (FDA) regarding Spero’s New Drug Application (NDA) for tebipenem HBr.
-
Spero is reducing a huge chunk of its staff to minimize expenses and reallocate resources toward more promising projects in anticipation of the FDA's decision on its NDA for tebipenem HBr.
-
Spero Therapeutics to Present Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases
4/21/2022
Spero Therapeutics, Inc. announced two oral presentations and four poster presentations at the 32nd European Congress of Clinical Microbiology and Infectious Diseases being held April 23-26, 2022, in Lisbon, Portugal.
-
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine
4/6/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from the Phase 3 ADAPT-PO clinical trial for its investigational oral carbapenem antibiotic, tebipenem pivoxil hydrobromide (tebipenem HBr).
-
Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update
3/31/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced financial results for the fourth quarter and full-year ended December 31, 2021 and provided a business update.
-
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 31, 2022
3/17/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that it will host a conference call and live audio webcast on Thursday, March 31, 2022, at 4:30 p.m. ET to report its fourth quarter and full-year 2021 financial results and provide an update on its business and pipeline.
-
Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206
2/16/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206.
-
Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients
1/19/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA) are expanding their existing partnership to develop tebipenem as a treatment for complicated urinary tract infections (cUTI).
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720
1/4/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero’s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease.
-
The FDA decided to lift the hold for its Phase IIa trial of SPR720 after Spero submitted a comprehensive analysis from the NHP toxicology study.
-
Today, the FDA approved two new drug applications. One is for Spero's tebipenem HBr oral tablets and the second is CStone's IND application for CS5001.
-
Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis
1/3/2022
Spero Therapeutics, Inc., announced that the U.S. Food and Drug Administration has granted Priority Review designation and confirmed the acceptance for substantive review of the New Drug Application seeking approval for tebipenem HBr oral tablets for treatment in adult patients with complicated urinary tract infections, including acute pyelonephritis, caused by susceptible microorganisms.
-
Spero Therapeutics to Present at Upcoming Investor Conferences
11/17/2021
Spero Therapeutics, Inc. today announced that Ankit Mahadevia, M.D. will present and be available for one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference and the 4th Annual Evercore ISI HealthCONx Conference.
-
Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update
11/10/2021
Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced financial results for the third quarter ended September 30, 2021, and provided a business update.